SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rika Naruse, Ken-ichiro Hori, Tomoko Terasawa, Kenji Hara, Mariko Suetsugu, Kohzo Takebayashi, Kimio Morita, Yoshimasa Aso, Toshihiko Inukai, Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients, Obesity Research & Clinical Practice, 2014,

    CrossRef

  2. 2
    Noriko Oza, Hirokazu Takahashi, Yuichiro Eguchi, Yoichiro Kitajima, Takuya Kuwashiro, Eriko Ishibashi, Shunya Nakashita, Shinji Iwane, Yasunori Kawaguchi, Toshihiko Mizuta, Iwata Ozaki, Naofumi Ono, Takahisa Eguchi, Kazuma Fujimoto, Keizo Anzai, Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease, Hepatology Research, 2014, 44, 7
  3. 3
    Mariana Verdelho Machado, Helena Cortez-Pinto, Management of fatty liver disease with the metabolic syndrome, Expert Review of Gastroenterology & Hepatology, 2014, 1

    CrossRef

  4. 4
    Shira Zelber-Sagi, Federico Salomone, Hanny Yeshua, Roni Lotan, Muriel Webb, Zamir Halpern, Erwin Santo, Ran Oren, Oren Shibolet, Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease, Liver International, 2014, 34, 6
  5. 5
    Minjie Lin, Shuiping Zhao, Li Shen, Danyan Xu, Potential Approaches to Ameliorate Hepatic Fat Accumulation Seen with MTP Inhibition, Drug Safety, 2014, 37, 4, 213

    CrossRef

  6. 6
    Yumie Takeshita, Toshinari Takamura, Masao Honda, Yuki Kita, Yoh Zen, Ken-ichiro Kato, Hirofumi Misu, Tsuguhito Ota, Mikiko Nakamura, Kazutoshi Yamada, Hajime Sunagozaka, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko, The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial, Diabetologia, 2014, 57, 5, 878

    CrossRef

  7. 7
    Giovanni Musso, Roberto Gambino, Maurizio Cassader, Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis, Progress in Lipid Research, 2013, 52, 1, 175

    CrossRef

  8. 8
    Wataru Tomeno, Masato Yoneda, Kento Imajo, Yuji Ogawa, Takaomi Kessoku, Satoru Saito, Yuichiro Eguchi, Atsushi Nakajima, Emerging drugs for non-alcoholic steatohepatitis, Expert Opinion on Emerging Drugs, 2013, 18, 3, 279

    CrossRef

  9. 9
    Sung-Woo Park, Intestinal and Hepatic Niemann-Pick C1-Like 1, Diabetes & Metabolism Journal, 2013, 37, 4, 240

    CrossRef

  10. 10
    KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease, Clinical and Molecular Hepatology, 2013, 19, 4, 325

    CrossRef

  11. 11
    Akinobu Nakamura, Yasuo Terauchi, Lessons from Mouse Models of High-Fat Diet-Induced NAFLD, International Journal of Molecular Sciences, 2013, 14, 11, 21240

    CrossRef

  12. 12
    Akinobu Takaki, Daisuke Kawai, Kazuhide Yamamoto, Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH), International Journal of Molecular Sciences, 2013, 14, 10, 20704

    CrossRef

  13. 13
    Angel Brea, José Puzo, Non-alcoholic fatty liver disease and cardiovascular risk, International Journal of Cardiology, 2013, 167, 4, 1109

    CrossRef

  14. 14
    Derrick M. Van Rooyen, Lay T. Gan, Matthew M. Yeh, W. Geoffrey Haigh, Claire Z. Larter, George Ioannou, Narci C. Teoh, Geoffrey C. Farrell, Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome, Journal of Hepatology, 2013, 59, 1, 144

    CrossRef

  15. 15
    Christopher Savard, Erica V. Tartaglione, Rahul Kuver, W. Geoffrey Haigh, Geoffrey C. Farrell, Savitha Subramanian, Alan Chait, Matthew M. Yeh, LeBris S. Quinn, George N. Ioannou, Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis, Hepatology, 2013, 57, 1
  16. 16
    Toshiaki Teratani, Kengo Tomita, Takahiro Suzuki, Tetsuya Oshikawa, Hirokazu Yokoyama, Katsuyoshi Shimamura, Susumu Tominaga, Sadayuki Hiroi, Rie Irie, Yoshikiyo Okada, Chie Kurihara, Hirotoshi Ebinuma, Hidetsugu Saito, Ryota Hokari, Kazuo Sugiyama, Takanori Kanai, Soichiro Miura, Toshifumi Hibi, A High-Cholesterol Diet Exacerbates Liver Fibrosis in Mice via Accumulation of Free Cholesterol in Hepatic Stellate Cells, Gastroenterology, 2012, 142, 1, 152

    CrossRef

  17. 17
    George N Ioannou, Beyond obesity: Is cholesterol-induced liver injury the cause of non-alcoholic steatohepatitis?, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  18. 18
    Kaori Kikuchi, Uru Nezu, Koji Inazumi, Takashi Miyazaki, Kanako Ono, Kazuki Orime, Jun Shirakawa, Koichiro Sato, Hirofumi Koike, Tadashi Wakasugi, Misako Sato, Chihiro Kawakami, Shinichiro Watanabe, Tadashi Yamakawa, Yasuo Terauchi, Double-Blind Randomized Clinical Trial of the Effects of Ezetimibe on Postprandial Hyperlipidaemia and Hyperglycaemia, Journal of Atherosclerosis and Thrombosis, 2012, 19, 12, 1093

    CrossRef

  19. 19
    Hiroyuki Takase, Yasuaki Dohi, Tateo Okado, Tomomi Hashimoto, Yoshie Goto, Genjiro Kimura, Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study, European Journal of Clinical Investigation, 2012, 42, 12
  20. 20
    Takashi Nakahara, Hideyuki Hyogo, Yuki Kimura, Tomokazu Ishitobi, Koji Arihiro, Hiroshi Aikata, Shoichi Takahashi, Kazuaki Chayama, Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study, Hepatology Research, 2012, 42, 11
  21. 21
    Noboru Tamaki, Hiroaki Ueno, Yuta Morinaga, Tomomi Shiiya, Masamitsu Nakazato, Ezetimibe Ameliorates Atherosclerotic and Inflammatory Markers, Atherogenic Lipid Profiles, Insulin Sensitivity, and Liver Dysfunction in Japanese Patients with Hypercholesterolemia, Journal of Atherosclerosis and Thrombosis, 2012, 19, 6, 532

    CrossRef

  22. 22
    Hiroaki Yagyu, Shuichi Nagashima, Manabu Takahashi, Michiaki Miyamoto, Kenta Okada, Jun-ichi Osuga, Shun Ishibashi, Ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein, decreases cholesteryl ester transfer protein in type 2 diabetes mellitus, Endocrine Journal, 2012, 59, 12, 1077

    CrossRef

  23. 23
    Masafumi Ono, Is rosuvastatin effective for non-alcoholic steatohepatitis with dyslipidemia?, Hepatology Research, 2012, 42, 11
  24. 24
    Thuy-Anh Le, Rohit Loomba, Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis, Journal of Clinical and Experimental Hepatology, 2012, 2, 2, 156

    CrossRef

  25. 25
    Tuyet A T Nguyen, Arun J Sanyal, Pathophysiology guided treatment of nonalcoholic steatohepatitis, Journal of Gastroenterology and Hepatology, 2012, 27,
  26. 26
    Fernando Bril, Romina Lomonaco, Kenneth Cusi, The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease, Clinical Lipidology, 2012, 7, 4, 471

    CrossRef

  27. 27
    Shinya Hiramitsu, Kenji Miyagishima, Junichi Ishii, Shigeru Matsui, Hiroyuki Naruse, Kenji Shiino, Fumihiko Kitagawa, Yukio Ozaki, The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load, Journal of Cardiology, 2012, 60, 5, 395

    CrossRef

  28. 28
    Giovanni Musso, Maurizio Cassader, Roberto Gambino, Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease, Current Opinion in Lipidology, 2011, 22, 6, 489

    CrossRef

  29. 29
    Soo Jin Yang, Jung Mook Choi, Lisa Kim, Byung-Joon Kim, Jin Hee Sohn, Won Jun Kim, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim, Cheol-Young Park, Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes, Biochemical and Biophysical Research Communications, 2011, 407, 1, 153

    CrossRef

  30. 30
    Hideyuki Hyogo, Tadashi Ikegami, Katsutoshi Tokushige, Etsuko Hashimoto, Kazuo Inui, Yasushi Matsuzaki, Hironori Tokumo, Fumiaki Hino, Susumu Tazuma, Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study, Hepatology Research, 2011, 41, 11
  31. 31
    Lin Jia, Jenna L. Betters, Liqing Yu, Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport, Annual Review of Physiology, 2011, 73, 1, 239

    CrossRef

  32. 32
    Venessa Pattullo, Mark W Douglas, Jacob George, Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?, Expert Review of Gastroenterology & Hepatology, 2011, 5, 2, 265

    CrossRef

  33. 33
    Mariko Hojo, Sumio Watanabe, Pharmacological therapy of nonalcoholic steatohepatitis, Hepatology Research, 2011, 41, 3
  34. 34
    A. S. Wierzbicki, The ezetimibe Jonah: the trials and tribulations of an unlucky drug, International Journal of Clinical Practice, 2011, 65, 12
  35. 35
    Mohamed H. Ahmed, Christopher D. Byrne, Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?, Drug Discovery Today, 2010, 15, 15-16, 590

    CrossRef

  36. 36
    Giovanni Musso, Federica Molinaro, Elena Paschetta, Roberto Gambino, Maurizio Cassader, Lipid Modifiers and NASH: Statins, Ezetimibe, Fibrates, and Other Agents,